Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne Therapeutics: A Buy, With Caveats, On DMD Progress

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Biotech ETF Index Surges 10% After Rebalance

Dyne Therapeutics Appoints Barry Greene to Board of Directors

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)